Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Continuous treatment with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in
disease relapse, with variable delay. Objective of this study was to compare efficacy between
a continuous treatment with infliximab, and a treatment adapted to symptoms recurrence.
Addition of methotrexate (MTX)to infliximab was also tested.